ORIX USA brings investment dollars that will enable TD2 to expand; help grow Arizona’s biomedical economy
SCOTTSDALE, Ariz., and DALLAS, Texas — Dec.18th, 2013 — ORIX USA Health and Life Sciences has completed an investment into Translational Drug Development (TD2) through the purchase of equity from the Translational Genomics Research Institute (TGen).
TGen will remain a significant minority equity holder in TD2, which has been a for-profit subsidiary of the non-profit TGen.
ORIX USA, a Dallas-based diversified financial conglomerate with nearly $ 5 billion in assets and $30 billion of assets under management, will provide the capital needed to enable TD2 to expand its capabilities to assist pharmaceutical companies in the development of new drugs based on the specific molecular profile of individual cancer patients.
Dr. Jeffery Trent, TGen President and Research Director; Dr. Daniel Von Hoff, TGen Physician In Chief; and former TGen executive Richard Love, founded TD2 in 2003 to accelerate cancer research and rare disease drug development for global pharmaceutical and leading academic institutions.
Under the leadership of President and CEO Dr. Stephen Gately, TD2 has managed and designed hundreds of preclinical and clinical engagements that have measurably improved the drug discovery process in one of humans’ most complex disease areas, cancer. TD2’s unique approach to patient identification, high throughput computational chemistry, and advanced genomic and diagnostic data analysis, gives the company a distinct and sustainable scientific advantage towards accelerate drug discovery in the fields of oncology and rare disease.
ORIX USA and TD2 will establish a unique and capital-efficient drug development model that leverages TD2’s broad capabilities and oncology expertise with ORIX’s international financial and operational resources.
Dr. Gately and existing management will continue to lead the company at their headquarters on the Mayo Clinic campus in Scottsdale.
“TD2 is excited to partner with ORIX USA Health and Life Sciences because of their knowledge and expertise in growing life science companies,” Dr. Gately said. “Working together we will focus on the rapid development of effective new medicines for patients with cancer.”
John Amos, CEO of ORIX USA Health and Life Sciences said, “ORIX is excited and privileged to work with the world-class scientists at TD2 and TGen. I have looked for a TD2-like company that combines scientific expertise and a focus on capital efficient drug discovery for the better part of a decade. We are thankful that TGen and TD2 have selected ORIX as their capital and development partner for their next phase of growth.”
An independent assessment of TD2’s economic impact performed by Pittsburgh-based Tripp Umbach predicted that by 2015 TD2 and its affiliations would have a total annual economic impact of $239 million, generating 1,080 jobs and producing $6.6 million annually in direct and indirect tax revenues for the City of Scottsdale.
Gov. Jan Brewer hailed the TGen-ORIX USA partnership as a key example of the benefits of supporting Arizona bioscience.
“This partnership shows that we can grow and diversify the Arizona economy in ways that will pay dividends in expanded jobs and revenues now, and exponentially in the future,” Gov. Brewer said.
Dr. Trent said the growth and expansion possibilities brought about by ORIX USA will over the long-term add to TD2’s value and provide great potential for creating clinical benefit.
“There is a high demand for TD2’s integrated suite of tools that inform clinical development plans,” Dr. Trent said. “By aligning with ORIX, we can move more rapidly in expanding our reach, which has the potential for bringing increased benefit to patients in need of ground-breaking therapies.”
“The investment from ORIX USA into TD2 speaks to the value-creation that TGen brings to Arizona, and in this case specifically to Scottsdale,” said Tess Burleson, TGen Chief Operating Officer and President of TGen Accelerators. “This transaction showcases TGen’s strength in bringing bioscience investment dollars from out-of-state to Arizona.”
# # #
Translational Drug Development (TD2) is an oncology development organization that provides innovative services for oncology-focused biopharmaceutical companies. Using a dedicated team of professionals with broad experience and understanding in drug development, TD2 is uniquely positioned to support improved and accelerated development of medicines for life-threatening diseases. TD2 applies rigorous and high-throughput translational preclinical development, combined with regulatory affairs expertise, to customize clinical trial design and execution. TD2’s suite of capabilities encourages the timely selection of patient populations most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. TD2 is committed to reducing the risks and uncertainty inherent in the drug development process and to the acceleration of patient access to promising treatments. For more information, visit: www.td2inc.com.
ORIX USA is a Dallas-based diversified financial conglomerate with nearly $5 billion in assets and $30 billion under management. ORIX USA Corporation is the U.S. subsidiary of ORIX Corporation, a publicly owned Tokyo-based international financial services company established in 1964. ORIX Corporation is listed on the Tokyo (8591) and New York (NYSE:IX) stock exchanges. For more information, visit: www.orix.com
Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. TGen is focused on helping patients with cancer, neurological disorders and diabetes, through cutting edge translational research (the process of rapidly moving research towards patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and rare complex diseases in adults and children. Working with collaborators in the scientific and medical communities literally worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: www.tgen.org.
TD2 is an oncology development organization that provides innovative services for oncology-focused companies. Using a dedicated team of professionals with broad experience and understanding in drug development, TD2 is uniquely positioned to support improved and accelerated development of medicines for life-threatening oncology diseases. TD2 applies rigorous and high-throughput translational preclinical development, combined with regulatory affairs expertise, to customize clinical trial design and execution. TD2’s suite of capabilities encourages the timely selection of patient populations who are most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. TD2 is committed to reducing the risks and uncertainty inherent in the drug development process and to the acceleration of patient access to promising treatments. For more information, visit www.TD2inc.com.